Hansa Biopharma AB (publ) (STO:HNSA)
25.10
-0.28 (-1.10%)
May 13, 2025, 5:29 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 66.35M SEK in the quarter ending March 31, 2025, with 18.52% growth. This brings the company's revenue in the last twelve months to 181.68M, up 9.53% year-over-year. In the year 2024, Hansa Biopharma AB had annual revenue of 171.32M with 27.76% growth.
Revenue (ttm)
181.68M
Revenue Growth
+9.53%
P/S Ratio
9.37
Revenue / Employee
1.32M
Employees
135
Market Cap
1.70B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.24B |
Sectra AB | 3.30B |
Getinge AB | 35.57B |
Camurus AB | 1.87B |
Medicover AB | 23.56B |
AddLife AB | 10.42B |
Vitrolife AB | 3.61B |
Vimian Group AB | 4.24B |
Hansa Biopharma AB News
- 16 hours ago - Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. - PRNewsWire
- 19 days ago - Hansa Biopharma AB (publ) (HNSBF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Hansa Biopharma AB (publ) 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 19 days ago - Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results - PRNewsWire
- 7 weeks ago - Hansa Biopharma publishes 2024 Annual and Sustainability Reports - PRNewsWire
- 2 months ago - Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients - PRNewsWire
- 3 months ago - Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire